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Background: Mutations in the tumor suppressor gene TP53 and proto-oncogene PIK3CA and alterations of p53 and
PIK3CA AKT mTOR pathways are common events in several human cancers. We focused on the analysis of TP53 and
PIK3CA gene variations in adenocarcinoma, squamous cell carcinoma as well as in intraepithelial neoplasia grade 3
of the cervix.
Methods: DNA samples from 28 cervical adenocarcinoma, 55 squamous cell carcinoma and 31 intraepithelial
neoplasia grade 3 (CIN3), previously characterized in terms of human papillomavirus (HPV) prevalence and
genotype distribution, were analyzed for TP53 and PIK3CA mutations in the exons 4–9 and exon 9, respectively.
Results: Single nucleotide substitutions in TP53 and PIK3CA genes were detected in 36% and 11% of
adenocarcinoma, in 16% and in 5% of squamous cell carcinoma, and in 13% and none of CIN 3, respectively.
Nucleotide changes in TP53 were significantly more frequent in adenocarcinoma cases than in squamous cell
carcinoma and CIN3 (P = 0.035) and were independent from HPV infection status.
Conclusions: Mutations in the TP53 gene and to lesser extent in the PIK3CA gene seem more frequent in cervical
adenocarcinoma than in squamous cell carcinoma and CIN3. Whether TP53 and PIK3CA gene mutations have an
impact on prognosis and response to molecularly targeted therapies as well as in cytotoxic drugs in different
cervical cancer histotypes needs to be analyzed in investigative clinical trials.
Keywords: TP53 gene, PIK3CA gene, Cervix, Squamous cell carcinoma, Adenocarcinoma, Cervical intraepithelial
neoplasiaIntroduction
Cervical cancer is the fourth most common cancer
diagnosed in women worldwide with an estimated
527,624 new cases and 265,653 deaths in 2012 [1].
The major histopathologic types are squamous cell
carcinoma and adenocarcinoma which constitute
about 85% and 10-12% of all cases of cervical cancer,
respectively. The squamous cell carcinoma arises in
the squamocolumnar junction between the ectocervi-
cal squamous epithelium and the endocervical colum-
nar epithelium and is preceded by a long phase of* Correspondence: m.tornesello@istitutotumori.na.it
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article, unless otherwise stated.cervical intraepithelial neoplasia (CIN1, CIN2 and
CIN3) [2]. The adenocarcinoma originates from glan-
dular precursor lesions of the endocervical mucosa
and comprises several histological subtypes such as
the mucinous adenocarcinoma (intestinal, endocervical
or signet-ring), the endometrioid and non-mucinous
adenocarcinoma (clear cell, serous) [3].
Oncogenic HPVs, mainly HPV 16 and 18 genotypes,
have been strongly associated with the risk to develop
intraepithelial lesions, squamous cell carcinoma and
adenocarcinoma of the cervix [4]. However, the majority
of HPV infections induce low grade squamous epithelial
lesions that in more than 90% of cases spontaneously re-
gress and in about 10% become transforming infections,
characterized by several molecular changes [5]. The earlytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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expressed in HPV-related cancers and derived tumor cell
lines and contribute to the transformation of infected
epithelial cells mainly through the inactivation of p53
and pRb oncosuppressors and related pathways [6].
However, the constitutive expression of early viral genes
is not in itself sufficient to induce and maintain the
transformation status and accumulation of genetic and/
or epigenetic alterations over time may be crucial for the
ultimate progression to cancer [5,7,8].
A number of studies have demonstrated that adenocar-
cinoma has worse prognosis with higher rates of metasta-
ses and decreased survival compared with squamous cell
carcinoma [9]. However, few studies have examined
whether distinct molecular profiles underlie the patho-
genesis of the two types of cervical cancer.
Several cellular genes such as TP53 [10,11], PIK3CA
[12], c-Myc (Myc) and ErbB2 [13], cIAP1 [14], Ras [15],
PTEN [16] and LKB1 [17] have been found mutated or
functional inactivated in variable proportions of cervical
cancers. Comprehensive analysis of genomic aberrations
in cervical tumors allowed to identify, besides the pre-
viously characterized mutations in TP53 and PIK3CA
genes, unknown mutations in MAPK1, HLA-B, EP300,
FBXW7, NFE2L2, and ERBB2 genes in squamous cell
carcinoma and somatic mutations of ELF3 (13%) and
CBFB (8%) genes in adenocarcinomas [18].
Mutations in TP53 gene are among the most common
genetic alterations in many human malignancies [19-23].
Up to 90% of TP53 mutations are non-synonymous and
determine single amino-acid changes primarily within the
DNA binding domain region (exon 5–8) located between
codons 125 and 300 [24]. In a recent meta-analysis,
including 1353 cervical tumors the frequency of non-
synonymous mutations in the DNA-binding domain of
the TP53 gene was found significantly higher in adeno-
carcinoma (32 of 241; 13.3%) compared to squamous cell
carcinoma (39 of 657; 5.9%; P = 0.0003, χ2 test), [10]. The
proportion of adenocarcinoma with mutated TP53 varied
from 4% in North America to 19% in Asia. Among the six
hot-spot codons of TP53 gene only three codons (175, 248
and 273) were found commonly mutated in both types of
cervical cancer. No study, however, has systematically
analyzed the frequency of TP53 mutations in different
histological types of adenocarcinoma, in squamous cell
carcinoma and in pre-invasive neoplastic lesions of the
cervix [10].
A number of studies reported that the phosphoinosi-
tide-3-kinase-catalytic-alpha (PIK3CA) gene is frequently
mutated in the helical domain within exon 9 (codons 542
and 545) and in the kinase domain within exon 20 (codon
1047) of several types of human cancer [25]. In cervical
cancer activating mutations in PIK3CA gene have been
found almost exclusively in exon 9 [18,26-28]. Knowledgeof mutational status of PIK3CA gene is particularly rele-
vant considering that several anticancer drugs, targeting
PI3K/Akt pathway, have given promising preliminary re-
sults in human malignancies [29]. McIntyre et al. (2013)
have recently reported that in cervical cancer patients
treated with radical chemoradiotherapy the PIK3CA
mutation status was strongly associated with overall sur-
vival in FIGO stage IB/II but not stage III/IVA [26]. In
addition, PIK3CA mutations in patients with advanced
breast, ovarian, endometrial, and cervical cancers have
been found associated with a higher response rate to treat-
ments that include PI3K/AKT/mTOR inhibitors [30].
These observations suggest that PIK3CA could represent
a potential drug targetable molecule for the treatment of
cervical cancer.
We performed a retrospective study investigating the
frequency of TP53 and PIK3CA mutations in pre-
treatment biopsies from a cohort of patients with mucin-
ous and non-mucinous adenocarcinoma, squamous cell
carcinoma and CIN 3 and we correlated the TP53 and
PIK3CA mutational status with histological subtypes and
HPV status.
Materials and methods
Patient and tissue samples
One hundred and fourteen formalin-fixed and paraffin-
embedded cervical neoplasia biopsies from patients
referred to the Gynecology Unit at the National Cancer
Institute Fond Pascale, from 2002 to 2008, were included
in the study. All cases have been previously characterized
in terms of histology, DNA quality and HPV genotypes
[31,32]. In particular, from each paraffin block, an initial
10-μm thick section was obtained for hematoxylin–eosin
staining, followed by four 10 μm sections that were col-
lected in separate sterile Eppendorf tubes for PCR analysis.
Slides immediately adjacent to the tissue section used for
gene mutation analysis were reviewed by the pathologist
to verify the presence of neoplastic tissue. This morpho-
logical check showed that the mean percentage of tumour
cells staining was 64% (range 10–100%). Histological sub-
types were determined in accordance to Young et al. [33]
and to The Bethesda 2001 system. Tissues were graded as
mucinous adenocarcinoma (endocervical and intestinal
types, n = 12), non-mucinous adenocarcinoma (endome-
trioid, clear cell and serous types, n = 14), mixed adenocar-
cinoma (n = 2), invasive squamous cell carcinoma (n = 55)
and CIN 3, according to the highest grade present within
a lesion.
Genomic DNA was extracted according to published
procedures [34]. In particular tissue samples were deparaf-
finized in xylenes and digested with Proteinase K (150 μg
per ml at 60°C for 30 min) in 100 μl of lysis buffer
(10 mM Tris–HCl pH 7.6, 5 mM EDTA, 150 mM NaCl,
1% SDS), followed by DNA purification by phenol and
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and ethanol precipitation in 0.3 M sodium acetate (pH
4.6). The study was approved by the institutional review
board of the Istituto Nazionale Tumori Pascale.
TP53 codon 4–9 mutational analysis
The analysis of TP53 gene in exons 4–9 was performed
using specific oligonucleotides and amplification protocols
according to the IARC guidelines (http://www-p53.iarc.fr/
Download/TP53_DirectSequencing_IARC.pdf). All PCR
reactions were undertaken using 10 to 100 ng genomic
DNA in 50-μL reaction mixture following the IARC amp-
lification procedures using in all reactions the Hot Master
buffer and the Hot Master Taq DNA Polymerase (5 Prime
GmbH, Hamburg, Germany). DNAs were amplified in a
Perkin-Elmer GeneAmp PCR System 9700 thermal cycler.
All samples with sufficient amount of DNA were
subjected to bidirectional direct sequencing analysis by
Primm Srl Laboratories (Milan, Italy).
PIK3CA codon 9 mutational analysis
PIK3CA codon 9 was amplified by a seminested PCR
using in the outer reaction the oligoprimer PIK3-9-F1
(5′- TGGTCTTGTT GTTGGCTAA) with PIK3-9-R1
(5′- CTTACCTGTGACTCCATAGAA), generating a 410
bp, and in the inner reaction the oligoprimer PIK3-9-F2
(5′- ACTATTCTGTGACTGGTGTAAT) with PIK3-9-R1,
generating a 381 bp fragment encompassing the hot spot
codons 542 and 545 and designed to avoid amplification
of the PIK3CA pseudogene. PCR reactions were per-
formed in 50 μL reaction mixture containing 50 to 100 ng
of target DNA, 5 pmol of each primer, 2.5 mM MgCl2,Table 1 TP53 and PIK3CA mutations and tumor clinical charac
TP53 mutant TP53 wild type
(n = 23) (n = 91)
Variable n (%) n (%)
Mean age [SD] 48.7 [±10.6] 51.4 [±14.7]
Histology
Adenocarcinoma (n = 28) 10 (36) 18 (64)
Squamous carcinoma (n = 55) 9 (16) 46 (84)
CIN 3 (n = 31) 4 (13) 27 (87)
Grading***
G1 (n = 5) 0
G2 (n = 23) 7 (30) 16 (70)
G3 (n = 55) 12 (22) 43 (78)
HPV status
Negative (n = 37) 10 (27) 27 (73)
Positive (n = 77) 13 (17) 64 (83)
*χ2for trend = 4.44.
**Fisher exact test.
***Well differentiated (G1); Moderately differentiated (G2); Poorly differentiated carc50 mM of each dNTP and 5 ul Hot Master buffer and 1 U
of Hot Master Taq DNA Polymerase (5 Prime GmbH,
Hamburg, Germany). DNA was amplified in a Perkin-
Elmer GeneAmp PCR System 9700 thermal cycler with
the following steps: an initial 1-min denaturation at 94°C,
followed by 45 amplification cycles of 58°C for 30 sec,
72°C for 30 sec, 94°C for 30 sec and a 1-min final annea-
ling at 58°C followed by 5-min elongation at 72°C. All
samples were subjected to bidirectional direct sequencing
analysis.
Statistical analyses
The planned test for statistical evaluation were Fisher’s
exact test, Yates corrected χ2 test or χ2 test for trend,
as appropriate, to compare the proportions of cases
mutated in TP53 or PIK3CA genes among patients
stratified by, age, tumour hystotype and HPV infection.
All analyses were performed with Epi Info 6 Statistical
Analysis System Software (6.04d, 2001, Centers for
Disease Control and Prevention, USA). Differences were
considered to be statistically significant when P values
were less than 0.05.
Results
A total of 114 patients with cervical adenocarcinoma,
squamous cell carcinoma and CIN 3 were analyzed for the
presence of mutations in exons 4–9 of TP53 and exon 9
of PIK3CA genes (Table 1). Twenty-eight patients (25%)
were diagnosed with adenocarcinoma carcinoma, 55
(48%) with squamous cell carcinoma and 31 (27%) with
CIN 3. The prevalence of high risk HPV was 72% in
adenocarcinoma, 85% in squamous cell carcinoma andteristics (n = 114)
P value PI3KCA mutant PIK3CA wild type P value
(n = 6) (n = 108)
0.326 56.9 [±10.5] 50.9 [±14.5] 0.364
0.035* 0.400**
3 (11) 25 (89)




1 (4) 22 (96)
5 (9) 50 (91)
4 (11) 33 (89)
2 (3) 75 (97)
inoma (G3).
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genotype in all histological categories being present in
67%, 81% and 74% of HPV-related adenocarcinoma, squa-
mous cell carcinoma and CIN 3, respectively [31,32].
TP53 gene was mutated in 10 out of 28 (36%) adenocar-
cinoma, in 9 out of 55 (16%) squamous cell carcinoma
and in 4 out of 31 (13%) of CIN 3 cases. In particular 46%,
7.9% and 15.3% of HPV16-positive adenocarcinoma, squa-
mous cell carcinoma and CIN3, respectively, harbored
mutations in TP53 gene. One out of nine (11.1%) squa-
mous cell carcinoma positive for high risk HPVs other
than type 16 was mutated in TP53 gene. None of adeno-
carcinoma and CIN3 cases positive for high risk HPVs
other than type 16 were mutated in the exons 4–9 of
TP53 gene. Among HPV-negative samples 50%, 75% and
7.1% of adenocarcinoma, squamous cell carcinoma andTable 2 Histological characteristics of cervical samples, HPV s
Patient no Histology HPV
AC206 Mucinous Endocervical Adenocarcinoma HPV16
AC134 Mucinous Endocervical Adenocarcinoma HPV16
AC174 Mucinous Endocervical Adenocarcinoma Neg
AC213 Mucinous Endocervical Adenocarcinoma HPV16
AC214 Mucinous Endocervical Adenocarcinoma HPV16
AC198 Mucinous Endocervical Adenocarcinoma Neg
AC193 Mucinous Endocervical Adenocarcinoma Neg
AC201 Mucinous Endometrioid Adenocarcinoma HPV16
AC218 Mucinous Endometrioid Adenocarcinoma HPV16
AC199 Non-mucinous Serous Adenocarcinoma Neg
AC210 Non-mucinous Serous Adenocarcinoma HPV16
SCC005 Squamous Cell Carcinoma Neg
SCC008 Squamous Cell Carcinoma Neg
SCC010 Squamous Cell Carcinoma Neg
SCC107 Squamous Cell Carcinoma HPV16
SCC022 Squamous Cell Carcinoma HPV16
SCC032 Squamous Cell Carcinoma HPV16
SCC036 Squamous Cell Carcinoma HPV45
SCC045 Squamous Cell Carcinoma Neg
SCC052 Squamous Cell Carcinoma Neg
SCC034 Squamous Cell Carcinoma Neg
SCC006 Squamous Cell Carcinoma HPV16
SCC019 Squamous Cell Carcinoma Neg
SCC064 Squamous Cell Carcinoma Neg
CIN085 Cervical Intraepithelial Neoplasia 3 HPV16
CIN090 Cervical Intraepithelial Neoplasia 3 Neg
CIN099 Cervical Intraepithelial Neoplasia 3 HPV16CIN3, respectively, were mutated in the TP53. The most
common nucleotide changes were missense mutations
(n = 17) affecting the DNA binding domain of p53
(Table 2). Interestingly, in 5 cases the single nucleotide
substitution appeared as an homozygous mutation sug-
gesting that major genetic alterations including loss of
heterozygosity affected chromosome 17 (Figure 1). No in-
sertion or deletions were detected. TP53 mutations were
significantly more frequent in adenocarcinoma (χ2 for
trend =4.44, P = 0.035), mainly in the mucinous endocer-
vical adenocarcinoma histotype (54%), compared to squa-
mous cell carcinoma and CIN3 (Table 3). The combined
mutational pattern of TP53 and PIK3CA genes showed
that a relevant proportion of nucleotide changes was rep-
resented by C:G > T:A transitions (39%) potentially arising
from deamination of DNA bases.tatus, TP53 (exons 4–9) and PIK3CA (exon 9) mutations
TP53 Mut PIK3CA Mut
E T231N C > A
E,18 M237K T > A
C258C A > T
G295N A > T
AA S095F C > T
E S090S C > T
P092L C > T E547K G > A
A307S G > T S541Y C > A
E E286E A > G
E Q546Q G > A
M237I G > C
Y236C A > G
Y163C A > G
H296H C > T
I162I C > T
int 14077 C > T
P250T C > A
I255I C > T
G245D G > A
S260T T > A
Y236T C > T
E545A A > C
E545K G > A
D527N G > A
C242C C > T
V143A T > C
Y95Y C > T
R282W C > T
int 13305 C > T
AC198 Cod92 CCC>CTC Pro>Leu AC214 Cod90 TCC>TCT Ser
SCC005 Cod163 TAC>TGC Tyr>Cys SCC052 Cod236 TAC>TAT Tyr SCC036 Cod245 GGC>GAC Gly>Asp 
AC213 Cod95 TCT>TTT Ser>Phe 
T
Figure 1 DNA sequence electropherograms showing nucleotide mutations in exons 4–9 of TP53 gene. Representative examples of
heterozygous mutations (sample AC213) and homozygous mutations (samples AC214, AC198, SCC005, SCC036, SCC052).
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TP53 gene mutation frequency between HPV-positive
and HPV-negative samples in all histological groups.
The exon 9 of PIK3CA gene was found mutated in six
(5%) out of 114 cases (Table 1). Non-synonymous muta-
tions were identified in three (11%) of the adenocarcinomas
at codons 541 (TCT >TAT, Ser > Tyr), 546 (CAG>CAA,
Gln > Gln) and 547 (GAG>AAG, Glu > Lys), and in all
three cases the sequence electropherograms showed ho-
mozygous mutations suggestive of major chromosomalTable 3 Frequency of TP53 and PIK3CA mutations in
cervical adenocarcinoma according to histological
subtypes
TP53 Mut PIK3CA Mut
Diagnosis n (%) n (%)
Mucinous adenocarcinoma
Endocervical (n = 11) 6 (54) 2 (18)
Intestinal (n = 1) 0 0
Endometrioid (n = 8) 2 (25) 1 (12)
Non-mucinous adenocarcinoma
Clear cell (n = 2) 0 0
Serous (n = 4) 2 (40) 0
Mixed adenocarcinoma (n = 2)* 0 0
All adenocarcinoma (n = 28) 10 (36) 3 (11)
*Serous/Glassy cells Adenocarcinoma (n = 1); Intestinal/signet ring cell
Adenocarcinoma (n = 1).aberrations affecting the 3q26.3 loci (Figure 2). Heterozy-
gous mutations in PIK3CA gene were found in three cases
(5%) of squamous cell carcinoma at codons 527 (GAC >
AAC, Asp > Asn) and 545 (GAG > AAG, Glu > Lys;
GAG > GCG, Glu > Ala). Two of the three PIK3CA
mutated samples were HPV negative. No mutation in
PIK3CA gene was detected in DNA samples extracted
from CIN3 samples.
Discussion
Persistent infection with high risk HPVs, the increased ex-
pression of E6 and E7 oncoproteins and HPV integration
into human DNA, along with chromosomal aberrations
and gene alteration at the integration sites, are considered
significant features of progression from pre-invasive to in-
vasive cervical cancer [5,35,36]. Few studies, however, have
systematically analyzed genetic alterations in HPV-related
genital cancers and their significance for cancer staging
and as predictive biomarkers.
In this study we observed that 20% of cervical neoplasia
cases were mutated in TP53 gene. The prevalence was
highest in adenocarcinoma (36%), followed by squamous
cell cervical cancer (16%) and CIN3 (13%). Although the
small number of cases analyzed in this study precludes de-
finitive conclusions regarding the absolute difference in
mutation rates among the different histological types of
cervical cancer groups, the results are in agreement with
data obtained from COSMIC databes [10]. However,
AC198  int  74600 G>A AC198  int  74671 A>G AC198  cod 547 GAG>AAG Glu>Lys
AC193 cod 541 TCT>TAT Ser>Tyr AC218 cod 546 CAG>CAA Gln>GlnSCC006 cod 545 GAG>AAG Glu>Lys 
A
Figure 2 DNA sequence electropherograms showing nucleotide mutations in exon 9 of PIK3CA gene. Representative examples of
heterozygous mutations (sample SCC006) and homozygous mutations (samples AC193, AC218, AC198).
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of TP53 gene and different mutation profiles of other
genes in adenocarcinoma and squamous cell carcinoma.
Specifically, in squamous cell carcinomas mutations in-
cluded recurrent E322K substitutions in the MAPK1 gene
(8%), inactivating mutations in the HLA-B gene (9%), and
mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%),
TP53 (5%) and ERBB2 (6%). In adenocarcinoma variations
included somatic mutations in ELF3 (13%) and CBFB (8%)
genes [18]. On the other hand, the identification of KRAS
mutations in 17% of adenocarcinoma and in none of squa-
mous carcinoma samples strongly suggests that they have
distinct molecular profiles [28].
The pattern of TP53 mutations was similar in cer-
vical adenocarcinoma and squamous cell carcinoma and
showed an excess of C:G to T:A transitions. This type of
mutations, which are the most common in all human
cancers, may originate from spontaneous nucleotide chan-
ges deriving from deamination of methyl-cytosine [4].
However, it is unclear whether their relative high fre-
quency in cervical cancer may be related to a specific car-
cinogen or to the excess of oxygen and nitrogen radicals
produced by oxidant-generating enzymes during chronic
inflammation [37-41]. We found an excess of TP53 muta-
tions in the mucinous endocervical histotype (54%), how-
ever no other study to date addressed the issue of gene
mutation distribution across the different subtypes ofadenocarcinoma such as endocervical, endometrioid, in-
testinal, and mixed adenocarcinoma.
Very few studies have analyzed the possible association
between mutations in TP53 gene and prognosis or treat-
ment outcome in adenocarcinoma and squamous cell
carcinoma of the cervix. One study has explored whether
p53 status, HPV, and LOH on chromosome 3p21.3,
6p21.2, 17p13.1 (on which TP53 gene is located), and
18q21.2 are associated with prognosis and treatment out-
come in 60 patients with squamous cell carcinoma and 5
with adenocarcinoma of the cervix after radiotherapy.
Statistical significant differences were observed between
tumor size and clinical stage (P = 0.0006), p53 status
(P = 0.045), and LOH on 17p13.1 (P = 0.02) [42]. No sig-
nificant differences in the overall survival and disease-free
survival between patients with wild-type p53 and those
with mutant p53 were observed in their study. Although,
the statistical analysis was hampered by the small number
of cases with mutant TP53 (10.8% of carcinomas).
We analyzed exon 9 of PIK3CA gene, encoding for the
highly conserved helical domain of the p110alpha catalytic
subunit of PI3K, and identified mutations in 11% of adeno-
carcinoma and 5% of squamous cell cervical cancer (5%)
and no mutations in the pre-invasive lesions. These results
are in agreement with PIK3CA mutation frequencies re-
ported in COSMIC (Catalogue of Somatic Mutations in
Cancer) database (11% and 14% in adenocarcinoma and
Tornesello et al. Journal of Translational Medicine 2014, 12:255 Page 7 of 9
http://www.translational-medicine.com/content/12/1/255squamous cell carcinoma, respectively) and with those re-
cently obtained by whole exome sequencing analysis of
cervical cancer genomes (PIK3CA mutation frequencies of
12.5% and 12.6% in adenocarcinoma and squamous cell
carcinoma, respectively) [18,43]. Moreover, Cui et al. [44]
analyzing exon 1, 9 and 20 of PIK3CA gene in cervical car-
cinomas and CIN3 lesions identified somatic mutations in
8.15% of cervical carcinomas but no mutations in CIN3
cases suggesting that genetic alterations of this proto-
oncogene are late events during carcinogenesis. Much
higher frequencies of PIK3CA mutations, however, were
found both in adenocarcinoma (37.5%) and in cervical
squamous carcinoma (25%) by mass-spectrometry based
analyses [28,45], suggesting either that this technique is
much more sensitive than Sanger sequencing or that
cancer cases from different populations have different rates
of PIK3CA mutations.
Interestingly in our study PIK3CA gene showed homo-
zygous nucleotide substitutions in all mutated adenocar-
cinoma suggesting that major genetic alterations affected
the locus 3q26.3, where the PIK3CA gene is located. In-
deed, a recent meta-analysis showed that the most fre-
quent chromosomal aberrations in cervical carcinoma
(SCC) occurred as gains (0.55, 95% CI 0.43–0.70) or
losses at 3p (0.36, 95% CI 0.27–0.48), specifically at the
3q25-3q29 loci [46]. Genomic gains of locus 3q26 have
been associated with the progression from high-grade
cervical disease to cancer being detected at lower rate in
earlier stages of cervical carcinogenesis and shown to in-
crease with the severity of cervical lesions [47-51]. No
study has yet investigated the correlation between the
mutation frequency of PIK3CA gene and 3q chromo-
somal aberration frequency.
Mutated PIK3CA gene is becoming a promising target
for newly discovered anticancer drugs. Janku et al. re-
ported that among patients affected by advanced breast,
cervical, endometrial, and ovarian cancers, those with
PIK3CA mutations treated with PI3K/AKT/mTOR in-
hibitors demonstrated a higher response rate than patients
without mutations [30]. In particular among the 23
PIK3CA-mutant patients with breast and gynecologic
cancers who experienced treatment failure with standard
therapies, was observed a response rate of 30%, which is
significantly favorable compared to a 10% response rate in
cancer patients with wild type PIK3CA treated on the
same protocols (P = 0.04) [30]. Moreover, McIntyre et al.
reported an association between tumoral PIK3CA muta-
tional status and overall survival in patients with cervical
cancer treated with radical chemo-radiotherapy. In par-
ticular the PIK3CA mutation status was strongly asso-
ciated with overall survival in FIGO stage IB/II patients,
unadjusted hazard ratio 6.0 (95% CI 2.1–17.5), p = 0.0002,
but not stage III/IVA patients, unadjusted hazard ratio 1.0
(95% CI 0.32–3.1), p = 0.98 [26]. Further prospectiveclinical trials evaluating patients with PIK3CA positive tu-
mors are required to evaluate response to targeted agents
such as PI3K inhibitors.
The main limitations of our study include the small
sample size and the retrospective design that do not
allow the appropriate evaluation of the clinical signifi-
cance of TP53 and PIK3CA mutants in terms of overall
survival, metastasis-free survival and outcome to thera-
pies. Prospective longitudinal studies are needed to de-
fine if the knowledge of TP53 and/or PIK3CA status
could provide relevant information for the management
of individual patients with different histotypes of adeno-
carcinoma and squamous cell carcinoma of the cervix.
Conclusions
In conclusion, our results show distinct mutation pro-
files in TP53 and PIK3CA genes in cervical adenocar-
cinoma, squamous cell carcinoma and CIN3. Knowledge
of genetic alterations in different cervical cancer histo-
types, in addition to currently used viral testing, may
provide a basis for future research directions in early
diagnostics and personalization of therapy.
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